Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04417621
Title Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Recruitment Active, not recruiting
Gender
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | child | adult
Covered Countries USA | ITA | FRA | DEU | BEL

Facility Status City State Zip Country Details
The Angeles Clinic and Research Institute Los Angeles California 90025 United States Details
UCSF Medical Center San Francisco California 94143 United States Details
Florida Cancer Specialists Sarasota Office Fort Myers Florida 33901 United States Details
H Lee Moffitt Cancer Center and Research Institute Moffitt McKinley Outpatient Ct Tampa Florida 33612 United States Details
Massachusetts General Hospital Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Dept.of DFCI Boston Massachusetts 02215 United States Details
Mayo Clinic Mayo Rochester Rochester Minnesota 55905 United States Details
NYU Laura and Isaac Perlmutter Cancer Center New York New York 10016 United States Details
Memorial Sloan Kettering Dept. of MSKCC New York New York 10017 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213 United States Details
University of TX MD Anderson Cancer Center Houston Texas 77030 United States Details
Novartis Investigative Site Caba Buenos Aires C1426ANZ Argentina Details
Novartis Investigative Site Buenos Aires C1125ABE Argentina Details
Novartis Investigative Site North Sydney New South Wales 2060 Australia Details
Novartis Investigative Site Wooloongabba Queensland 4102 Australia Details
Novartis Investigative Site Subiaco Western Australia 6008 Australia Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site Lille Cedex 59037 France Details
Novartis Investigative Site Marseille Cedex 05 13885 France Details
Novartis Investigative Site Paris Cedex 10 75475 France Details
Novartis Investigative Site Pierre Benite Cedex 69495 France Details
Novartis Investigative Site Toulouse Cedex 9 31059 France Details
Novartis Investigative Site Villejuif Cedex 94800 France Details
Novartis Investigative Site Dresden 01307 Germany Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Tübingen 72076 Germany Details
Novartis Investigative Site Ramat Gan 52621 Israel Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Maastricht 6229 HX Netherlands Details
Novartis Investigative Site Oslo 0379 Norway Details
Novartis Investigative Site Lausanne 1011 Switzerland Details
Novartis Investigative Site Zuerich 8091 Switzerland Details
Novartis Investigative Site London NW1 2BU United Kingdom Details
Novartis Investigative Site Manchester M20 2BX United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field